
DeepCure: Accelerating affordable AI-powered drug discovery for better, faster results.
DeepCure, founded with the mission to revolutionize small-molecule drug discovery, leverages advanced AI technology to deliver more effective drugs faster and at a lower cost. The company focuses on transforming the pharmaceutical industry by integrating cutting-edge robotics and artificial intelligence to streamline and enhance the drug development process. DeepCure aims to make high-quality treatments more accessible and affordable, addressing critical healthcare needs globally.
Notable figures associated with DeepCure include a distinguished leadership team and a robust scientific advisory board comprising experts in AI and drug discovery. The company has attracted significant investment from prominent venture capital firms, underscoring its potential impact. Key achievements include the development of a sophisticated AI-driven platform that accelerates the identification and optimization of therapeutic candidates. DeepCure's innovative approach has positioned it as a leader in the biotech industry, promising substantial advancements in patient care and treatment efficacy.

Deep Apple Therapeutics
deepappletx.com

Cognaisent
cognaisent.com

Immunocure Discovery Solutions
immunocure.us

DeepBiome Therapeutics

Insitro
insitro.com

Atomic AI
atomic.ai

Terray Therapeutics
terraytx.com

Biosim

TandemAI
tandemai.com

Aureka Biotechnologies
aurekabio.com

Zephyr AI
zephyrai.bio

Curie.Bio
curie.bio

Celeris Therapeutics
celeristx.com

Model Medicines
modelmedicines.com

AMPLY Discovery
amplydiscovery.com
Companies similar to DeepCure include Deep Apple Therapeutics, Cognaisent, Immunocure Discovery Solutions and DeepBiome Therapeutics.
DeepCure was founded in 2018.
DeepCure's headquarters is located in Boston, MA, US.
DeepCure's most recent funding round was for $40M (USD) in November 2021.
As of Nov 8, 2021, DeepCure has raised a total of $40M (USD).
DeepCure has 39 employees as of Feb 4, 2024.